Article Sidebar
Views PDF: 778
EVALUATE THE EFFECTIVENESS OF CHEMOTHERAPY WITH ABVD REGIMEN IN HODGKIN LYMPHOMA AT CHO RAY HOSPITAL IN 2015-2020
Main Article Content
Abstract
Background: Hodgkin Lymphoma is a type of lymphomas, derived from lymphocytes, calculated 10% of all lymphomas and 0,6% type of cancers in generally. For a historical perpective, Hodgkin lymphoma can be achieved approximately 80% with initial treatment. Studies have proved the effectiveness and safety of chemotherapy with ABVD regimen in Hodgkin Lymphoma. Subjects and Research method: Subject: Patients who have been diagnosed to be affected by Hodgkin lymphoma, agrees to used initial treatment with ABVD at Cho Ray hospital during 2015-2020. Research method: Short cut description, retrospective. Results: During 2015-2020, we have researched 72 cases Hodgkin lymphoma with characteristics: Median age: 32 (range: 15-69 years), male/female: 1,4/1. Site of origin: cervical nodes(44,4%), mediastinal nodes (31,9%). Patients had stages II,IV involved in 44,4% and 31,9%. Response completely after 8 cycles is 62,5%; partly response is 31,9%. After radiology therapy, Response completely is 88,9%. Side effects of medications mainly is nausea and neutropenia. Overall, the five years OS and PFS rate were 87,5% and 84,7%. Conclusion: Studies have proved the effectiveness and safety of chemotherapy with ABVD regimen in Hodgkin Lymphoma
Article Details
Keywords
Lymphoma Hodgkin, ABVD regimen, Complete Response, Partial Response, No Response, Progressive Disease, Relapse Disease
References
2. Nguyễn Trường Sơn, Trần Thanh Tùng, Lê Phước Đậm, Lâm Mỹ Hạnh (2011) "Đánh giá hiệu quả phác đồ ABVD trong điều trị lymphoma hodgkin tại khoa huyết học Bệnh viện Chợ Rẫy năm 2006-2010". Tạp chí Y Học TP. Hồ Chí Minh, 15, (4).
3. Bonfante, V., Santoro, A., Viviani, S., Valagussa, P., Bonadonna, G. (1992) "ABVD in the treatment of Hodgkin's disease". Semin Oncol, 19, (2 Suppl 5), 38-44; discussion 44-5.
4. Canellos, G. P., Anderson, J. R., Propert, K. J., Nissen, N., Cooper, M. R., Henderson, E. S., Green, M. R., Gottlieb, A., Peterson, B. A. (1992) "Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD". N Engl J Med, 327, (21), 1478-84.
5. Gordon, L. I., Hong, F., Fisher, R., Hoppe, R. T., Horning, S. J. (2012) "Randomized Phase III Trial of ABVD Versus Stanford V With or Without Radiation Therapy in Locally Extensive and Advanced-Stage Hodgkin Lymphoma: An Intergroup Study Coordinated by the Eastern Cooperative Oncology Group (E2496)". Journal of Clinical Oncology, 31, (6), 684-691.
6. Mondello, P., Musolino, C., Dogliotti, I., Bohn, J., Cavallo, F., Ferrero, S., Botto, B., Cerchione, C., Straus, D. J. (2020) "ABVD vs BEACOPP escalated in advanced-stage Hodgkin’s lymphoma: Results from a multicenter European study". American Journal of Hematology, n/a, (n/a).
7. National Cancer Institute (2017), Common Terminology Criteria for Adverse Events (CTCAE), https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_8.5x11.pdf,
8. Shamoon, R. P., Ali, M. D., Shabila, N. P. (2018) "Overview and outcome of Hodgkin's Lymphoma: Experience of a single developing country's oncology centre". PloS one, 13, (4), e0195629-e0195629.
9. Vakkalanka, B., Link, B. K. (2011) "Neutropenia and Neutropenic Complications in ABVD Chemotherapy for Hodgkin Lymphoma". Advances in hematology, 2011, 656013-656013.